531 related articles for article (PubMed ID: 36341760)
1. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.
Zou Y; Xie J; Zheng S; Liu W; Tang Y; Tian W; Deng X; Wu L; Zhang Y; Wong CW; Tan D; Liu Q; Xie X
Int J Surg; 2022 Nov; 107():106936. PubMed ID: 36341760
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
3. Association Between Diverse Cell Death Patterns Related Gene Signature and Prognosis, Drug Sensitivity, and Immune Microenvironment in Glioblastoma.
Li J; Song Z; Chen Z; Gu J; Cai Y; Zhang L; Wang Z
J Mol Neurosci; 2024 Jan; 74(1):10. PubMed ID: 38214842
[TBL] [Abstract][Full Text] [Related]
4. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
5. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
[TBL] [Abstract][Full Text] [Related]
6. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
8. Identification and analysis of diverse cell death patterns in diabetic kidney disease using microarray-based transcriptome profiling and single-nucleus RNA sequencing.
Luo Y; Liu L; Zhang C
Comput Biol Med; 2024 Feb; 169():107780. PubMed ID: 38104515
[TBL] [Abstract][Full Text] [Related]
9. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs.
Pan W; Song K; Zhang Y; Yang C; Zhang Y; Ji F; Zhang J; Shi J; Wang K
Front Immunol; 2022; 13():982486. PubMed ID: 36119101
[TBL] [Abstract][Full Text] [Related]
10. Integrated multi-cohorts for characterizing the immunogenomic landscape and predicting drug response in triple-negative breast cancer.
Su D; Chi M; Wang S; Di S; Zhang H; Lu Q; Yu Y; Xiong Y; Wei H; Lv Y; Zuo Y; Yang L
Brief Funct Genomics; 2022 May; 21(3):188-201. PubMed ID: 35348574
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
12. Identification an innovative classification and nomogram for predicting the prognosis of thyroid carcinoma patients and providing therapeutic schedules.
Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14817-14831. PubMed ID: 37596371
[TBL] [Abstract][Full Text] [Related]
13. Turning up a new pattern: Identification of cancer-associated fibroblast-related clusters in TNBC.
Xie J; Zheng S; Zou Y; Tang Y; Tian W; Wong CW; Wu S; Ou X; Zhao W; Cai M; Xie X
Front Immunol; 2022; 13():1022147. PubMed ID: 36275659
[TBL] [Abstract][Full Text] [Related]
14. CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer.
Cheng T; Wu Y; Liu Z; Yu Y; Sun S; Guo M; Sun B; Huang C
Front Immunol; 2022; 13():970950. PubMed ID: 36052076
[TBL] [Abstract][Full Text] [Related]
15. Integrated profiling uncovers prognostic, immunological, and pharmacogenomic features of ferroptosis in triple-negative breast cancer.
Fang K; Xu Z; Jiang S; Yan C; Tang D; Huang Y
Front Immunol; 2022; 13():985861. PubMed ID: 36505498
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature.
Qin Y; Deng J; Zhang L; Yuan J; Yang H; Li Q
Aging (Albany NY); 2021 Feb; 13(4):5485-5505. PubMed ID: 33536349
[TBL] [Abstract][Full Text] [Related]
17. Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer.
Pu S; Zhou Y; Xie P; Gao X; Liu Y; Ren Y; He J; Hao N
Front Immunol; 2022; 13():964118. PubMed ID: 36059470
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic and prognostic role of cuproptosis-related genes in triple negative breast cancer.
Shi B; Zhang W; Wang T; Cui Z
BMC Bioinformatics; 2023 May; 24(1):223. PubMed ID: 37259036
[TBL] [Abstract][Full Text] [Related]
19. Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer.
Chen X; Li Z; Liang M; Zhang Z; Zhu D; Lin B; Zhou R; Lu Y
World J Surg Oncol; 2023 Jun; 21(1):194. PubMed ID: 37391802
[TBL] [Abstract][Full Text] [Related]
20. Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer.
Su P; Peng Z; Xu B; Yang B; Jin F
PeerJ; 2021; 9():e12383. PubMed ID: 34900411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
